Steven Gillis
QuietNamed in filings at ARCH Venture PartnersOn the current fund
- Board seats filed
- 29
Named in filings at ARCH Venture PartnersOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Basking Biosciences | Biotech & pharma | October 2023 | None on file |
| Skylark Bio | Biotech & pharma | August 2022 | None on file |
| SonoThera | Biotech & pharma | April 2022 | Domain Partners, Vida Ventures |
| Pheast Therapeutics | Biotech & pharma | January 2022 | None on file |
| hC Bioscience | Biotech & pharma | December 2021 | None on file |
| Ally Therapeutics | Biotech & pharma | July 2019 | None on file |
| Magnolia Neurosciences | Biotech & pharma | August 2018 | None on file |
| ImmusanT | Biotech & pharma | November 2017 | None on file |
| Proniras | Biotech & pharma | August 2017 | None on file |
| Rodeo Therapeutics | Biotech & pharma | July 2017 | Passage BIO Inc |
| eGenesis | Biotech & pharma | March 2017 | Aditum Bio, Kendall Capital Partners |
| Nohla Therapeutics | Biotech & pharma | November 2016 | None on file |
| ApoGen Biotechnologies | Biotech & pharma | November 2016 | None on file |
| VBI Vaccines Inc/BC | Biotech & pharma | June 2016 | Clarus |
| Petra Pharma | Biotech & pharma | December 2015 | Aditum Bio |
| Lodo Therapeutics | Biotech & pharma | December 2015 | None on file |
| Homology Medicines | Biotech & pharma | December 2015 | None on file |
| Codiak BioSciences | Biotech & pharma | November 2015 | None on file |
| OncoResponse | Biotech & pharma | September 2015 | Greatpoint Ventures Innovation, Rivervest |
| Pulmatrix | Biotech & pharma | June 2015 | Polaris Partners |
| Nexgenia | Biotech & pharma | June 2015 | None on file |
| Theraclone Sciences | Biotech & pharma | April 2015 | None on file |
| Pulmatrix Operating Company | Biotech & pharma | March 2015 | Polaris Partners |
| VBI VACCINES | Biotech & pharma | July 2014 | None on file |
| Faraday Pharmaceuticals | Biotech & pharma | July 2014 | Polaris Partners |
| LYCERA | Biotech & pharma | March 2014 | Aditum Bio |
| PHASERX | Biotech & pharma | February 2012 | Versant Affiliates, Versant Venture Capital |
| ALLOZYNE | Biotech & pharma | January 2012 | None on file |
| Variation Biotechnologies (US) | Biotech & pharma | December 2011 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Steven Gillis on the board, based on 29 filed seats with a verified or cited source.